ChiCTR-ONC-17010942 版本V1.0 版本创建时间2017/03/21 11:18:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-ONC-17010942 

最近更新日期:

Date of Last Refreshed on:

2017-03-21 11:15:40 

注册时间:

Date of Registration:

2017-03-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

糖尿病足下肢介入治疗有效性以及安全性临床观察研究

Public title:

The efficacy and safety of the interventional treatment for diabetic foot

注册题目简写:

English Acronym:

研究课题的正式科学名称:

糖尿病足下肢介入治疗有效性以及安全性临床观察研究

Scientific title:

The efficacy and safety of the interventional treatment for diabetic foot

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王渊 

研究负责人:

童强 

Applicant:

Wang Yuan 

Study leader:

Tong Qiang 

申请注册联系人电话:

Applicant telephone:

+86 18883641108

研究负责人电话:

Study leader's
telephone:

+86 023 68755079

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangyuan705@126.com

研究负责人电子邮件:

Study leader's E-mail:

tq237366315@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国重庆市沙坪坝新桥正街183号

研究负责人通讯地址:

中国重庆市沙坪坝区新桥正街183号

Applicant address:

183 Xinqiao Main Street, Shapingba District, Chongqing

Study leader's address:

183 Xinqiao Main Street, Shapingba District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国人民解放军第三军医大学第二附属医院

Applicant's institution:

Second Affiliated Hospital Third Military Medical University

研究负责人所在单位:

中国人民解放军第三军医大学第二附属医院

Affiliation of the Leader:

Second Affiliated Hospital Third Military Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-056-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军第三军医大学第二附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Second Affiliated Hospital of Third Military Medical University, PLA

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军第三军医大学第二附属医院

Primary sponsor:

Second Affiliated Hospital of Third Military Medical University

研究实施负责(组长)单位地址:

中国重庆市沙坪坝新桥正街183号

Primary sponsor's address:

183 Xinqiao Main Street, Shapingba District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

中国人民解放军第三军医大学第二附属医院

具体地址:

中国重庆市沙坪坝新桥正街183号

Institution
hospital:

Second Affiliated Hospital of Third Military Medical University

Address:

183 Xinqiao Main Street, Shapingba District, Chongqing

经费或物资来源:

国家自然科学基金面上项目

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

糖尿病足  

Target disease:

diabetic foot

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

单臂 

Study design:

Single arm 

研究目的:

1.介入治疗对糖尿病足患者治疗的有效性 2.介入治疗对糖尿病足患者治疗的安全性  

Objectives of Study:

1. The efficacy of the interventional treatment for diabetic foot; 2. The safety of the interventional treatment for diabetic foot.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.有足部溃;2.Rutherford分级3级以上;3.下肢血管CTA提示血管狭窄

Inclusion criteria

1. Foot ulcers;
2. The stage 3 of Rutherford;
3. the CTA show lower limb vascular stenosis.

排除标准:

① 不能表达或理解知情同意;② 无法或不愿完成研究所需要的流程;③ 正在参与干预性临床试验;④ 妊娠期或哺乳期妇女;⑤ HIV感染或艾滋病患者;⑥ 心功能IV级或存在致死性心率失常;⑦ 肾功能衰竭(CKD5期);⑧ 对碘剂过敏;⑨ 近期有活动性出血以及凝血功能障碍;

Exclusion criteria:

1. pregnant women;
2. HIV patient;
3. Cardiac function grade IV or fatal arrhythmia;
4. the fifth stage of CKD;
5. Allergic to iodine6. active hemorrhage or coagulation disorders.

研究实施时间:

Study execute time:

From 2017-03-22 00:00:00 To 2019-03-21 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-03-22 00:00:00 To 2018-03-21 00:00:00

干预措施:

Interventions:

组别:

介入组

样本量:

100

Group:

interventional group

Sample size:

干预措施:

介入

干预措施代码:

Intervention:

interventional treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

中国人民解放军第三军医大学第二附属医院 

单位级别:

三甲医院 

Institution
hospital:

Second Affiliated Hospital of Third Military Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

踝肱指数

指标类型:

主要指标

Outcome:

Ankle brachial pressure index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

经皮氧分压

指标类型:

主要指标

Outcome:

transcutaneous oxygen pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

glycosylated hemoglobin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不需要随机方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random method is not required.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过网络平台共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the end of the trial, use chictr.org.cn platform open

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用Excel表格及图表方式

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

the Excel was used to save data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-03-21 11:15:41